

medication we used benzodiazepines (anxiolytics and hypnotics). The group's average at the HDRS was 46 points.

After 30 days there was an improvement on 9 patients (82%), with a HDRS average score of 30 points. After 90 days there was an improvement on 10 patients (91%), and the HRDS average score was 14. After 120 days the HRDS average score of those 10 patients was 8 points.

One of the patients had no response and the treatment had to be reinforced. Only two of them had side-effects, like nausea, constipation, tremulousness and restlessness. We believe that duloxetine is one of the first choices as a treatment for melancholy.

P0031

Pooled analysis of the safety and tolerability of desvenlafaxine Succinate compared with placebo in the treatment of major depressive disorder

A.H. Clayton¹, S.G. Kornstein², L. Lamm³, G. Rosas³, K.A. Tourian³. ¹University of Virginia, Charlottesville, VA, USA ²Virginia Commonwealth University, Richmond, VA, USA ³Wyeth Research, Collegeville, PA, USA

Objective: To characterize the safety and tolerability of desvenlafaxine succinate (DVS) in patients with major depressive disorder (MDD).

Methods: Pooled data from 7 double-blind, placebo-controlled studies were analyzed. Adult outpatients with DSM-IV MDD received DVS or placebo for 8 weeks. Four studies employed flexible dosing of DVS (100-200mg/d [1 study]; 200-400mg/d [3 studies]); 3 studies evaluated fixed doses (100/200/400mg/d [1 study]; 200/400mg/d [2 studies]). Vital signs and treatment-emergent adverse events (TEAEs) were evaluated. In the fixed-dose subset of studies, dose-related effects were analyzed.

Results: The overall safety population consisted of 2014 patients (DVS: n=1211; placebo: n=803); 60% were women. Adverse events were responsible for discontinuations in 4% of placebo-treated patients and 15% of DVS-treated patients. Discontinuation rates increased with dose (10% with 100mg/d to 17% with 400mg/d) in the subset of fixed-dose studies. TEAEs were consistent with the serotonin-norepinephrine reuptake inhibitor (SNRI) class. Nausea was generally mild to moderate with a median duration less than or = to 6 days; the incidence decreased to placebo-like rates after week 1. With all doses of DVS, small but statistically significant changes in mean blood pressure were observed. Mean changes in pulse rate and the proportion of potentially clinically important increases in sustained elevations in supine diastolic blood pressure were higher for patients receiving 200/400mg/d than among placebo-treated subjects; values for these parameters with the 100mg/d dose did not differ from placebo.

Conclusions: DVS treatment exhibited a safety and tolerability profile that was generally consistent with the SNRI class.

P0032

Effects of Escitalopram on the processing of emotional faces

W.C. Alves-Neto, V.G. Guappo, F.G. Graeff, C.M. Del-Ben. *Division of Psychiatry, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil*

Background and Aims: The aim of this study was to verify the effects of the selective serotonin reuptake inhibitor escitalopram on the recognition of facial emotional expressions.

Method: Twelve healthy males completed two experimental sessions each, separated by at least 2 weeks, in a randomized, balanced order, double-blind design. An oral dose of escitalopram (10 mg) or placebo was given 3 hours before the task. Face recognition task: Subjects were presented with pictures of faces from the Pictures of Facial Affect Series (Ekman and Friesen, 1976). Faces with six basic emotions (anger, disgust, fear, happiness, sadness and surprise) had been morphed between neutral (0%) and each standard emotion (100%), in 10% steps. Accuracy was analyzed through MANOVA with repeated measures. Values of $p < 0.05$ were considered significant.

Results: Volunteers recognized more accurately negative emotions in female faces than in male faces, whereas happiness was identified more easily in male faces. In general, the acute administration of a single dose of escitalopram increased the accuracy of the recognition of angry and sad faces. When the gender of the faces was analyzed, escitalopram facilitated the recognition of sad expressions and impaired the recognition of happy faces in male, but not in female faces. A global order effect has also been found; the administration of escitalopram in the second experimental session facilitated the recognition of emotional expressions.

Conclusions: These results indicate that serotonin modulates the recognition of emotional faces. Previous experience and gender of the emotional face interact with this modulation.

P0033

The impact of treatment on quality of life in major depressive disorder (MDD) and generalized anxiety disorder (GAD)

K. Demyttenaere. *Department of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium*

Objective: To compare the quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) in patients with MDD or GAD, before and after treatment and to compare remission based on symptoms versus functioning.

Methods: Q-LES-Q and symptom-specific MADRS and HAMA data from 8 published randomised, 8-week, double-blind, placebo-controlled clinical trials with escitalopram were used. The short form of the patient-rated Q-LES-Q was used to assess patients' perceived quality of life and satisfaction at baseline and at last assessment. ANCOVA was used, adjusting for study, centre, baseline value, and treatment. MADRS and HAMA total scores were equated to Q-LES-Q using the method of equipercentile linking.

Results: MDD or GAD patients report a substantial degree of impairment in their quality of life (64% and 76% of community norm, respectively). Treatment with escitalopram resulted in statistically and clinically significant improvement in patient quality of life. The improvement was greater in remitters (MADRS \leq 12 or HAMA \leq 7) than in non-remitters and greater in patients treated with escitalopram than in patients treated with placebo. There was a strong correlation between each symptom scale (MADRS, HAMA) and the Q-LES-Q. The present analyses suggest that scores as low as 3-8 on the MADRS and 5-10 on the HAMA (complete remission) correspond to a Q-LES-Q score of 58 (+/- 10%), found in community comparison subjects.

Conclusions: Treatment with escitalopram results in a statistically significant improvement of quality of life in patients with MDD or GAD.